Publications by authors named "Anissa Zarour"
Article Synopsis
- A study was conducted with 180 pregnant women and 168 nonpregnant women with immune thrombocytopenia (ITP) to assess the risks of ITP worsening during pregnancy and neonatal ITP (NITP).
- The findings showed that while pregnant women with ITP had a higher likelihood of severe thrombocytopenia recurrence and treatment changes, the overall risk of severe bleeding did not differ from nonpregnant women.
- NITP was identified in 14% of neonates, particularly linked to a mother's past history of NITP and low platelet counts close to delivery, providing valuable insights for advising women with ITP.
Article Synopsis
- A retrospective study evaluated the safety of three JAK inhibitors (ruxolitinib, tofacitinib, baricitinib) using data from the WHO database, focusing on their associated adverse events.
- The analysis found a significant link between these drugs and various adverse events, particularly infectious diseases, musculoskeletal issues, and certain cancers, with ruxolitinib showing a notable risk for viral, fungal, and mycobacterial infections.
- Tofacitinib was specifically associated with gastrointestinal perforations, while no significant increase in major cardiovascular events was reported across the drugs studied.
Rituximab is a second-line option in adults with immune thrombocytopenia (ITP), but the estimated 5-year response rate, only based on pooled retrospective data, is about 20%, and no studies have focused on long-term safety. We conducted a prospective multicenter registry of 248 adults with ITP treated with rituximab with 5 years of follow-up to assess its long-term safety and efficacy. The median follow-up was 68.
View Article and Find Full Text PDFThe benefit of belatacept on antibody-mediated rejection (ABMR) incidence after kidney transplant with preformed donor-specific antibodies (DSAs) has never been assessed. Between 2014 and 2016, we conducted a multicenter prospective clinical trial with 49 patients to determine kidney allograft outcome in recipients with preformed DSAs (maximal mean fluorescence intensity 500 to 3000) treated with belatacept (BELACOR trial). Immunosuppressive strategy included antithymocyte globulin, belatacept, mycophenolate mofetil, and steroids.
View Article and Find Full Text PDFAccurate estimation of the dose of ionizing radiation to which individuals have been exposed is critical for therapeutic treatment. We investigated whether gene expression profiles could be used to evaluate the dose received, thereby serving as a biological dosimeter. We used cDNA microarrays to monitor changes in gene expression profiles induced by ionizing radiation in mouse total blood.
View Article and Find Full Text PDF